Literature DB >> 35875463

Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.

Bianca Weinstock-Guttman1, Maria Pia Sormani2, Pavle Repovic3.   

Abstract

The ability to reliably monitor disease progression in patients with multiple sclerosis (MS) is integral to patient care. The Expanded Disability Status Scale (EDSS) is a commonly used tool to assess the disability status of patients with MS; however, it has limited sensitivity in detecting subtle changes in disability levels and, as a result, does not consistently provide clinicians with accurate insight into disease progression. At the 2019 European Committee for Treatment and Research in Multiple Sclerosis meeting in Stockholm, Sweden, a panel of neurologists met to discuss the limitations of the EDSS as a short-term predictor of MS progression. Before this panel discussion, a targeted literature review was conducted to evaluate published evidence on prognostic measures such as fatigue, physical assessments, and measures that are more taxing for patients, all of which may be useful to clinicians at different stages of the course of MS. This article summarizes currently available evidence in support of these measures. In addition, this article highlights the current state of expert clinical consensus regarding the current approaches used to predict and monitor disease progression and offers insight for future studies to assist clinicians in accurately monitoring disease progression in patients with MS.
© 2022 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  long-term disability; multiple sclerosis; predictive value

Year:  2022        PMID: 35875463      PMCID: PMC9296054          DOI: 10.7224/1537-2073.2020-114

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  29 in total

1.  Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Authors:  Caila B Vaughn; Katelyn S Kavak; Michael G Dwyer; Aisha Bushra; Muhammad Nadeem; Diane L Cookfair; Murali Ramanathan; Ralph Hb Benedict; Robert Zivadinov; Andrew Goodman; Lauren Krupp; Robert W Motl; Bianca Weinstock-Guttman
Journal:  Mult Scler       Date:  2018-12-03       Impact factor: 6.312

2.  Disability as an outcome in MS clinical trials.

Authors:  G C Ebers; L Heigenhauser; M Daumer; C Lederer; J H Noseworthy
Journal:  Neurology       Date:  2008-05-14       Impact factor: 9.910

3.  Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Authors:  Tomas Uher; Manuela Vaneckova; Jan Krasensky; Lukas Sobisek; Michaela Tyblova; Jana Volna; Zdenek Seidl; Niels Bergsland; Michael G Dwyer; Robert Zivadinov; Nicola De Stefano; Maria Pia Sormani; Eva Kubala Havrdova; Dana Horakova
Journal:  Mult Scler       Date:  2017-11-16       Impact factor: 6.312

4.  Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

Authors:  L Lavorgna; S Bonavita; D Ippolito; R Lanzillo; G Salemi; F Patti; P Valentino; G Coniglio; M Buccafusca; D Paolicelli; A d'Ambrosio; V Bresciamorra; G Savettieri; M Zappia; B Alfano; A Gallo; Il Simone; G Tedeschi
Journal:  Mult Scler       Date:  2013-07-09       Impact factor: 6.312

5.  Defining reliable disability outcomes in multiple sclerosis.

Authors:  Tomas Kalincik; Gary Cutter; Tim Spelman; Vilija Jokubaitis; Eva Havrdova; Dana Horakova; Maria Trojano; Guillermo Izquierdo; Marc Girard; Pierre Duquette; Alexandre Prat; Alessandra Lugaresi; Francois Grand'Maison; Pierre Grammond; Raymond Hupperts; Celia Oreja-Guevara; Cavit Boz; Eugenio Pucci; Roberto Bergamaschi; Jeannette Lechner-Scott; Raed Alroughani; Vincent Van Pesch; Gerardo Iuliano; Ricardo Fernandez-Bolaños; Cristina Ramo; Murat Terzi; Mark Slee; Daniele Spitaleri; Freek Verheul; Edgardo Cristiano; José Luis Sánchez-Menoyo; Marcela Fiol; Orla Gray; Jose Antonio Cabrera-Gomez; Michael Barnett; Helmut Butzkueven
Journal:  Brain       Date:  2015-09-10       Impact factor: 13.501

6.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

Review 7.  Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.

Authors:  Laura J Balcer; Jenelle Raynowska; Rachel Nolan; Steven L Galetta; Raju Kapoor; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

8.  Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Authors:  Robert W Motl; Jeffrey A Cohen; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

9.  Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Authors:  Tanuja Chitnis; Cindy Gonzalez; Brian C Healy; Shrishti Saxena; Mattia Rosso; Christian Barro; Zuzanna Michalak; Anu Paul; Pia Kivisakk; Camilo Diaz-Cruz; Neda Sattarnezhad; Isabelle V Pierre; Bonnie I Glanz; Davorka Tomic; Harald Kropshofer; Dieter Häring; David Leppert; Ludwig Kappos; Rohit Bakshi; Howard L Weiner; Jens Kuhle
Journal:  Ann Clin Transl Neurol       Date:  2018-10-16       Impact factor: 4.511

10.  Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years.

Authors:  Irene Pulido-Valdeolivas; Magí Andorrà; David Gómez-Andrés; Kunio Nakamura; Salut Alba-Arbalat; Erika J Lampert; Irati Zubizarreta; Sara Llufriu; Eloy Martinez-Heras; Elisabeth Solana; Nuria Sola-Valls; María Sepulveda; Ana Tercero-Uribe; Yolanda Blanco; Anna Camos-Carreras; Bernardo Sanchez-Dalmau; Pablo Villoslada; Albert Saiz; Elena H Martinez-Lapiscina
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.